PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma
PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.
Incyte’s Minjuvi combo gets Japan approval for relapsed follicular lymphoma
Incyte Biosciences Japan has secured approval from the Ministry of Health, Labour and Welfare for the use of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma. This marks the first regulatory authorization in Japan for a CD19-directed therapy in this indication and introduces a novel CD19–CD20 […]